2013-10-23 12:49:31 - Cepheid is pleased to announce the launch of its next generation Xpert Flu test for the GeneXpert® System, a CE IVD marked product offering on-demand STAT testing for triage, outbreaks, emergencies and high risk patient management.
In any healthcare environment, rapid, accurate diagnosis of influenza is vital for effective clinical management and infection control. Cepheid’s next generation Xpert Flu is the only molecular diagnostic test capable of providing on-demand results in just over an hour. With faster turnaround times for improved workflows, plus wider coverage, it enables real-time determination of Flu A and Flu B infection, as well as the identification of 2009 H1N1, maximising medical decision making. This leads to improved isolation and infection control measures, enhancing patient flow and bed use, and reducing the pressure on hospital resources.
Xpert Flu is a key component of Cepheid’s Winter Care Bundle – comprising of the Xpert Flu, Xpert SA Nasal Complete, Xpert C. difficile and
Xpert Norovirus rapid tests – an essential tool kit in the battle against highly transmissible infections, helping to reduce the potential for preventable ward closures.
For more information, visit www.cepheid.com/product-catalog/clinical-ivd-tests/xpert-flu
Based in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit www.cepheid.com